title: Successful treatment of an infant with veno-occlusive disease developed after allogeneic bone marrow transplantation by tissue plasminogen activator, heparin and prostaglandin E1.
abstract: A 15-month-old boy with severe aplastic anemia developed veno-occlusive disease (VOD) after allogeneic bone marrow transplantation (BMT), in which the preparative regimen included 50 mg/kg/day cyclophosphamide and anti-lymphocyte globulin for 4 consecutive days. The diagnosis was made based on clinical symptoms and data including, hepatomegaly, right upper quadrant abdominal pain, jaundice, ascites, coagulopathy and thrombocytopenia which was refractory to transfusions of platelet concentrate. We gave 2, 3, 5 and 5 mg/day/body of recombinant tissue plasminogen activator (tPA) followed by heparin and prostaglandin E1 (PGE1) effectively and without significant side effect on days 9, 10, 13 and 14, respectively. Clinical and biochemical improvement was steady and dramatic. We suggest that tPA following continuous heparin and PGE1 infusion may be useful in the treatment of VOD even in infantile cases.
authors.affiliation: Department of Pediatrics, Mie University School of Medicine, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Higashigawa
authors.forename: M
authors.initials: M
authors.lastname: Watanabe
authors.forename: H
authors.initials: H
authors.lastname: Nishihara
authors.forename: N
authors.initials: N
authors.lastname: Tabata
authors.forename: E
authors.initials: E
authors.lastname: Azuma
authors.forename: M
authors.initials: M
authors.lastname: Ido
authors.forename: M
authors.initials: M
authors.lastname: Ito
authors.forename: M
authors.initials: M
authors.lastname: Sakurai
mesh_terms: D000527:Alprostadil / Q000627:therapeutic use*; D000741:Anemia, Aplastic / Q000628:therapy; D016465:Bone Marrow Purging; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D006493:Heparin / Q000627:therapeutic use*; D006504:Hepatic Veno-Occlusive Disease / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D007223:Infant; D008297:Male; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*; D014184:Transplantation, Homologous
chemical_list: D006493:Heparin; D010959:Tissue Plasminogen Activator; D000527:Alprostadil